Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

both of which are positioned for indication expansions into severe asthma and COPD. The first biologic to enter the COPD market, Dupixent (dupilumab), has paved the way for competitors ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and ...

Besides Dupixent, the drug could also face strong ... This AZN drug is currently approved for two indications, namely eosinophilic asthma and EGPA. AstraZeneca is also evaluating the drug in ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

The success of Dupixent has demonstrated the viability ... Fasenra, already approved for severe asthma, builds on this progress with its ability to address eosinophilic inflammation, a key driver ...

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it ...